Premium
Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas
Author(s) -
Dinjens Winand N. M.,
Kate Joop Ten,
Kirch Jan A. J. M.,
Tanke Hans J.,
van der Linden Edith P. M.,
van den Ingh Harry F. G. M.,
van Steenbrugge Gert Jan,
Khan P. Meera,
Bosman Fred T.
Publication year - 1990
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1711600303
Subject(s) - immunohistochemistry , metastasis , pathology , adenocarcinoma , prostate , cytoplasm , prostate cancer , cancer , biology , medicine , cancer research , microbiology and biotechnology
The expression of the adenosine deaminase complexing protein (ADCP) was Investigated by immunohistochemistry in the normal and hyperplastic human prostate, in 30 prostatic adenocarcinomas, and in seven human prostatic adenocarcinoma cell lines grown as xenografts in athymic nude mice. In the normal and hyperplastic prostate, ADCP was localized exclusively in the apical membrane and the apical cytoplasm of the glandular epithelial cells. In prostatic adenocarcinomas, four distinct ADCP expression patterns were observed: diffuse cytoplasmic, membranous, both cytoplasmic and membranous, and no ADCP expression. The expression patterns were compared with the presence of metastases. We found an inverse correlation between membranous ADCP immunoreactivity and metastatic propensity. Exclusively membranous ADCP immunoreactivity occurred only in non‐metastatic tumours. In contrast, the metastatic tumours showed no or diffuse cytoplasmic ADCP immunoreactivity. This suggests that immunohistochemical detection of ADCP might predict the biological behaviour of prostatic cancer. However, the occurrence of membranous ADCP immunoreactivity in the xenograft of a cell line (PC‐EW), derived from a prostatic carcinoma metastasis, indicates that not only the tendency to metastasize modulates ADCP expression.